Guard therapeutics

See the webcast.

The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries. Financial Times Close. Search the FT Search.

Guard therapeutics

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC The company's Chief Medical Officer, Dr. CEO Tobias Agervald then presented new advancements in the company's preclinical development platform, the so-called GTX platform, aimed at developing new peptides short protein fragments based on the endogenous protein alphamicroglobulin. The overall goal is to identify new drug candidates tailored for the treatment of chronic diseases. The peptide GTX, along with other similar peptides, has demonstrated robust therapeutic effects in several experimental models representing various forms of kidney disease, including kidney injuries caused by oxygen deprivation known as ischemia-reperfusion injury and by the chemotherapy agent cisplatin.

A recording of the presentation is available on the company's website. TradeDoubler AB. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation, guard therapeutics.

.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. New preclinical results from the company's peptide platform will also be presented. The next developmental step includes a phase 2b study with the aim of identifying an optimal dosage of RMC The phase 2b study is also expected to enable the most efficient design of a subsequent pivotal phase 3 study.

Guard therapeutics

In line with previous communication patient recruitment was prematurely stopped, and as expected the primary short-term endpoint, incidence of acute kidney injury AKI within 72 hours after surgery, was not reached. Importantly though, pre-defined secondary endpoints demonstrated the intended long-term benefit of RMC with improved kidney function compared to placebo. These results clearly support advancement in the clinical development program and highlight the potential of RMC as a novel short-term treatment for kidney protection. With these results we are back on track, strengthened in our confidence to establish a new and unique treatment for the prevention of kidney injuries in heart surgery and proceed with the clinical development of RMC as planned. The consistency between improved kidney function and MAKE reduction in the stable phase after surgery is compelling because these outcome measures offer distinct perspectives on assessing the kidney-protective treatment effect. As the lead investigator of the AKITA trial, I am eager to see the compound's further development progress and ultimate contribution to improving patient outcomes," said Prof.

Fu wah chinese restaurant

The peptide GTX, along with other similar peptides, has demonstrated robust therapeutic effects in several experimental models representing various forms of kidney disease, including kidney injuries caused by oxygen deprivation known as ischemia-reperfusion injury and by the chemotherapy agent cisplatin. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Show more Personal Finance link Personal Finance. Acute kidney injury is a large market. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC ROSgard in kidney transplantation. Add to Your Portfolio New portfolio. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. Partnera Oyj. Press releases Event calender Analyses and presentations In media Subscribe. With these results, the company sees promising opportunities to strengthen and expand its position in several new potential therapy areas, including chronic kidney disease. Use our equities screener to discover other potential opportunities.

Acute kidney injury AKI affects millions of people annually and involves a rapid loss of kidney function because of various types of injuries to the kidneys.

Press releases Event calender Analyses and presentations In media Subscribe. Add to Your Portfolio New portfolio. Guard Therapeutics announced that the U. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Show more Opinion link Opinion. Click or tap a row for details. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC Show more Companies link Companies. Financial Times Close. HomeMaid AB publ. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. For further information, please contact:.